Market Cap | 90.77M | P/E | - | EPS this Y | -256.00% | Ern Qtrly Grth | - |
Income | -19.97M | Forward P/E | -5.12 | EPS next Y | 16.90% | 50D Avg Chg | -3.00% |
Sales | 20.14M | PEG | -0.06 | EPS past 5Y | - | 200D Avg Chg | -14.00% |
Dividend | N/A | Price/Book | 2.41 | EPS next 5Y | 100.00% | 52W High Chg | -39.00% |
Recommedations | 1.70 | Quick Ratio | 1.51 | Shares Outstanding | 10.79M | 52W Low Chg | 19.00% |
Insider Own | 19.76% | ROA | -15.77% | Shares Float | 6.17M | Beta | 0.84 |
Inst Own | 39.88% | ROE | -75.66% | Shares Shorted/Prior | 589.79K/638.65K | Price | 9.58 |
Gross Margin | 13.25% | Profit Margin | -99.17% | Avg. Volume | 13,416 | Target Price | 29.75 |
Oper. Margin | -88.56% | Earnings Date | Nov 19 | Volume | 6,048 | Change | -0.62% |
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
HC Wainwright & Co. | Buy | Aug 15, 24 |
HC Wainwright & Co. | Buy | Jul 16, 24 |
HC Wainwright & Co. | Buy | May 30, 24 |
HC Wainwright & Co. | Buy | Mar 22, 24 |
HC Wainwright & Co. | Buy | Jan 16, 24 |
HC Wainwright & Co. | Buy | Nov 22, 23 |
HC Wainwright & Co. | Buy | Sep 21, 23 |
Oppenheimer | Outperform | Aug 17, 23 |
HC Wainwright & Co. | Buy | Aug 17, 23 |